Promising early activity was observed in RET fusion–positive NSCLC as well as in RET mutant– and RET fusion–positive thyroid cancer, leading to FDA approval of selpercatinib in these disease-specific indications followed by tumor-agnostic approval (Drilon et al. 2020, Subbiah et al. 2022b, Wirth et al. 2020). This evidence concerns the gene RET and thyroid cancer.